Pay in 4 interest-free payments of $6.72 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
We detected GLP-1R and Pdx1 in cells by PCR, and the trend was also consistent with the trend of their protein expression (Figures 7G, H)
Zepbound raked in $4.3 billion in the fourth quarter, which was up 123% year over year and an increase from $3.6 billion in the third quarter and, Yee noted, the drug continues to show robust growth despite compounded injectable GLP-1 Wegovy. Lilly is projecting 2026 sales to come in at between $80 billion and $83 billion, Fierce Pharma reported this week
Sounds like theres a lot of potential here with this new program
PMID: 22304503
Weight loss typically continues, with clinical trials showing that semaglutide 2.4 mg (Wegovy) produces average weight loss of approximately 15% by week 68, while tirzepatide (Zepbound) has demonstrated weight loss of approximately 15-21% across different doses by week 72
